| Table 1A. Experiment 1: antibody levels at various times prior to and after infection with YF virus as determined by PRNT50 assay. | |||||||
|---|---|---|---|---|---|---|---|
| Group | Serum Pool used for treatment |
Serum pool Dilution |
PRNT50 geometric mean titer (GMT) at different times before and after virus challenge |
||||
| Treatment - 24 h |
Estimated passive titera -4 hoursb |
Observed titer -4 hoursc |
4 daysb (Seropositive/total, %Pos) |
21 daysb (Seropositive/total, %Pos)d |
|||
| 1 | XRX-001 | 1:10 | 4,100 | 136 | 75 | 32 (9/9, 100) | 12,900 (3/9, 33) |
| 2 | XRX-001 | 1:100 | 410 | 14 | 20 | 20 (3/10, 30) | 640 (4/9, 44) |
| 3 | XRX-001 | 1:1,000 | 41 | 1 | <10 | <10 (0/10, 0) | 403 (3/4, 75) |
| 4 | XRX-001 | 1:10,000 | 4 | 0.1 | NTe | <10 (0/10, 0) | 1,110 (5/6, 83) |
| 5 | YF-VAX® | 1:10 | 480 | 16 | 20 | <10 (0/9, 0) | 905 (4/7, 57) |
| 6 | YF-VAX® | 1:100 | 48 | 2 | <10 | <10 (0/8, 0) | 806 (3/5, 60) |
| 7 | YF-VAX® | 1:1,000 | 5 | 0.2 | NT | <10 (0/9, 0) | 453 (2/2, 100) |
| 8 | Saline + Alum | 1:10 | <10 | N/A | NT | <10 (0/8, 0) | 1,140 (6/7, 86) |
| 9 | XRX-001 (not challenged) | 1:10 | 4,100 | 273 | NT | 20 (3/3, 100) | <160 (0/3, 0) |
| Table 1B. Experiment 2: antibody levels at various times prior to and after infection with YF virus as determined by PRNT50 assay. | |||||||
|---|---|---|---|---|---|---|---|
| Group | Serum Pool used for treatment |
Serum pool Dilution |
PRNT50 geometric mean titer (GMT) at different times before and after virus challenge |
||||
| Treatment - 24 h |
Estimated passive titera -4 hoursb |
Observed titer -4 hoursb (Seropositive/total, %Pos) |
4 daysb (Seropositive/total, %Pos) |
21 daysb (Seropositive/total, %Pos) |
|||
| 1 | XRX-001 | 1:10 | 4,100 | 137 | 70c (10/10, 100%) | 21c (10/10, 100%) | 145 (7/10, 70%) |
| 3 | XRX-001 | 1:30 | 1,367 | 46 | 23 (5/6, 83%) | 10 (2/6, 33%) | 320 (4/5, 80%) |
| 5 | XRX-001 | 1:100 | 410 | 14 | 17 (8/10, 80%) | 10 (1/10, 10%) | 274 (9/9, 100%) |
| 7 | XRX-001 | 1:300 | 137 | 5 | 10 (2/9, 22%) | <10 (0/9, 0) | 453 (4/4, 100%) |
| 9 | YF-VAX® | 1:10 | 480 | 16 | 10 (5/10, 50%) | <10 (0/10, 0) | 285 (6/7, 86%) |
| 11 | YF-VAX® | 1:30 | 48 | 2 | <10 (0/10, 0%) | <10 (0/10, 0) | 640 (1/1, 100%) |
| 13 | Normal hamster serum | 1:10 | <10 | <10 | 10 (1/26, 4%) | <10 (0/26, 0) | 320 (6/6, 100%) |
a
Estimated titer based on dilution of 0.5mL inoculum in 7 mL blood volume of the hamster (1:15 dilution) and 50% distribution in the intravascular space, for a total dilution of 1:30
b
Time shown is hours (days) before/after challenge.
c
Serum sample volumes were insufficient to test individual animals for all groups, so sera from 2–8 animals were pooled and tested by PRNT50. See Figure 2 for serum pools and GMT results
d
Geometric means were calculated for the positives (>10) only
e
Not tested
a
Estimated titer based on dilution of 0.5mL inoculum in 7 mL blood volume of the hamster (1:15 dilution)
b
Time shown is hours (days) before/after challenge.
c
Geometric means were calculated for the positives (>10) only